Clinical Trial Update: Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease [Phase 3]

View source ↗

Summary

Open-label rollover study continuing valbenazine for the treatment of chorea in Huntington disease (Phase 3); currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Huntington Disease

Drugs mentioned

• INGREZZA (valbenazine)

Snippet

Sponsor: Neurocrine Biosciences | Conditions: Chorea, Huntington | Phase 3 | Status: ACTIVE_NOT_RECRUITING